BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 11575709)

  • 1. A clinical focus on statins.
    Auer J; Eber B
    Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U; Gathof BS
    Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use over time of statins in coronary patients in an Italian tertiary referral center.
    Gaspardone A; Proietti I; Altamura L; Tomai F; Versaci F; Crea F; Chiariello L; Gioffrè PA
    Ital Heart J; 2001 Nov; 2(11):848-53. PubMed ID: 11770871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective use of statins to prevent coronary heart disease.
    Crouch MA
    Am Fam Physician; 2001 Jan; 63(2):309-20, 323-4. PubMed ID: 11201696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
    Ray KK; Cannon CP; Ganz P
    Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 9. Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study.
    Kashima Y; Izawa A; Aizawa K; Koshikawa M; Kasai H; Tomita T; Kumazaki S; Tsutsui H; Koyama J; Ikeda U
    J Cardiol; 2009 Aug; 54(1):76-9. PubMed ID: 19632524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [For coronary disease patients is certain: the lower the LDL the better].
    MMW Fortschr Med; 2006 Jun; 148(24):6. PubMed ID: 16850797
    [No Abstract]   [Full Text] [Related]  

  • 11. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
    März W
    MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673
    [No Abstract]   [Full Text] [Related]  

  • 12. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD; Patel H
    Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
    Mills EJ; Rachlis B; Wu P; Devereaux PJ; Arora P; Perri D
    J Am Coll Cardiol; 2008 Nov; 52(22):1769-81. PubMed ID: 19022156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward a role for statins in immunomodulation.
    Mach F
    Mol Interv; 2002 Dec; 2(8):478-80. PubMed ID: 14993398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
    Lachaine J; Rinfret S; Merikle EP; Tarride JE
    Am Heart J; 2006 Jul; 152(1):164-9. PubMed ID: 16824851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania PC;
    Am Heart J; 2004 Dec; 148(6):1053-9. PubMed ID: 15632893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between statins on clinical endpoints: a population-based cohort study.
    Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
    Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
    Kumar A; Cannon CP
    J Interv Cardiol; 2007 Dec; 20(6):447-57. PubMed ID: 18042049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.